Please click here to obtain permission to reproduce this image.

Click on image to view larger version.



Figure 2 Serum levels of soluble VCAM-1 (ng/dl) were measured in subjects with known coronary artery disease (CAD) by enzyme-linked immunosorbent assay technique. Diamonds represent the change in sVCAM-1 levels over the 24-week study period at intervals of 0, 4, 12 and 24 weeks in patients with CAD treated with irbesartan. Squares represent sVCAM-1 levels measured in control patients over the study period at the same interval schedule. Values for CAD patient group represent mean ± SD. * = value differs (p < 0.001) from the control group. # = value differs (p < 0.001) from the CAD group before treatment with irbesartan. {diamondsuit} = CAD; {blacksquare} = control.